The Real‑World Effectiveness of Aumolertinib for Rare EGFR Mutations in Lung Cancer

Aumolertinib, a newer drug that targets the epidermal growth factor receptor (EGFR), has been tested in two hospitals on patients with a rare form of lung cancer. The cancer cells carry uncommon deletions in exon 19 of the EGFR gene, a pattern that often makes standard treatments less reliable. Researchers wanted to see how well second‑ and third‑generation EGFR inhibitors work when used as the first treatment for these patients. They followed people who started therapy with aumolertinib or other similar drugs and recorded how long the cancer stayed under control. The study found that aumolertinib can keep many patients’ tumors from growing for a significant period. The results suggest that even though the mutations are uncommon, targeted drugs still offer a meaningful benefit.However, the data also show that responses vary from person to person. Some patients experience a quick reduction in tumor size, while others see only modest improvement or develop resistance after a few months. These findings emphasize the need for personalized medicine: doctors should test for specific EGFR mutations before choosing a drug. In cases with rare exon 19 deletions, newer inhibitors like aumolertinib might be the best first choice. The research also highlights that real‑world evidence—data collected from everyday clinical practice—can complement controlled trials. It shows how patients actually respond outside of strict study protocols and can guide future treatment plans.